Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

liposome-encapsulated daunorubicin-cytarabine

View Patient Information
A liposomal formulation containing a fixed combination of the antineoplastic agents cytarabine and daunorubicin in a 5:1 molar ratio. Liposome-encapsulated daunorubicin-cytarabine has been designed to provide optimal delivery of a specific ratio of cytarabine to daunorubicin, one that has been shown to be synergistic in vitro. The antimetabolite cytarabine competes with cytidine for incorporation into DNA, inhibiting DNA synthesis. This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. Daunorubicin, an intercalator and a topoisomerase II inhibitor, prevents DNA replication and inhibits protein synthesis. This agent also generates oxygen free radicals, resulting in the cytotoxic lipid peroxidation of cell membrane lipids.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:cytarabine and daunorubicin liposomal
cytarabine-daunorubicin liposome for injection
liposomal AraC-daunorubicin CPX-351
liposomal cytarabine-daunorubicin
liposome-encapsulated combination of daunorubicin and cytarabine
US brand name:Vyxeos
Code name:CPX-351
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search